<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEO-FRADIN- neomycin sulfate solution </strong><br>X-GEN Pharmaceuticals, Inc.<br></p></div>
<h1>Neo-Fradin<br>Neomycin Sulfate Oral Solution, USP<br><br>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fc1610f0-3a42-43b5-82af-067732e6420f"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Warning">
<a name="LINK_57c4c71c-d738-4816-8689-dc4de322c3c7"></a><a name="section-2"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First">SYSTEMIC ABSORPTION OF NEOMYCIN OCCURS FOLLOWING ORAL ADMINISTRATION AND TOXIC REACTIONS MAY OCCUR. Patients treated with neomycin should be under close clinical observation because of the potential toxicity associated with their use.</p>
<p><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span> (INCLUDING <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">OTOTOXICITY</span>) AND <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span> FOLLOWING THE ORAL USE OF NEOMYCIN SULFATE HAVE BEEN REPORTED, EVEN WHEN USED IN RECOMMENDED DOSES. THE POTENTIAL FOR <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span>, PERMANENT BILATERAL AUDITORY <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">OTOTOXICITY</span> AND SOMETIMES VESTIBULAR TOXICITY IS PRESENT IN PATIENTS WITH NORMAL RENAL FUNCTION WHEN TREATED WITH HIGHER DOSES OF NEOMYCIN AND/OR FOR LONGER PERIODS THAN RECOMMENDED. Serial, vestibular, and audiometric tests, as well as tests of renal function, should be performed (especially in high risk patients).</p>
<p>THE RISK OF <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span> AND <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">OTOTOXICITY</span> IS GREATER IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span>.  <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> is often delayed in onset and patients developing cochlear damage will not have symptoms during therapy to warn them of developing eighth nerve destruction and total or partial <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> may occur long after neomycin has been discontinued.</p>
<p>Neuromuscular blockage and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> have been reported following the oral use of neomycin. The possibility of the occurrence of neuro-muscular blockage and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> should be considered if neomycin is administered, especially to patients receiving anesthetics, neuro-muscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary.</p>
<p>Concurrent and/or sequential systemic, oral, or topical use of other aminoglycosides including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin, and viomycin should be avoided because the toxicity may be additive.</p>
<p>Other factors which increase the risk of toxicity are advanced age and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided since certain diuretics by themselves may cause <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>. In addition, when administered intravenously, diuretics may enhance neomycin toxicity by altering the antibiotic concentration in serum and tissue.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_4fccc121-c181-4173-8af4-61ae191cb6e8"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NEO-FRADIN Oral Solution for oral administration contains neomycin which is an antibiotic obtained from the metabolic products of the actinomycete <span class="Italics">Streptomyces fradiae</span>. The pH range is 5.0 to 7.5. NEO-FRADIN Oral Solution is a clear orange solution with a cherry flavor. Each 5 mL of NEO-FRADIN Oral Solution contains 125 mg of neomycin sulfate (equivalent to 87.5 mg of neomycin).</p>
<p>Inactive ingredients: benzoic acid, FD&amp;C yellow no. 6, cherry flavor, glycerin, methylparaben, proplyparaben, sodium phosphate dibasic heptahydrate, sulfuric acid, and purified water.</p>
<p>Sodium phosphate dibasic heptahydrate and sulfuric acid are used as pH adjusters.</p>
<p>The chemical name for Neomycin is: <span class="Italics">0</span>-2, 6-diamino-2, 6-dideoxy-α-D-lucopyranosyl-(1→3)-<span class="Italics"> 0</span>β-D-ribofuranosyl-(1→5)<span class="Italics">0</span>-[2, 6-diamino-2, 6-dideoxy-α-D-glucopyranosyl-(1→4)]-2-deoxy-D-streptamine.</p>
<p>Neomycin B is identical except that the -α-D-glucopyranosyl residue in the neobiosamine moiety is β-L-idopyranosly.</p>
<p>The molecular weight of Neomycin is 614.67. The structural formula is represented below:</p>
<div class="Figure">
<img alt="neo descriptive text" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5&amp;name=neo-fradin-solution-1.jpg"><p class="MultiMediaCaption">neomycin molecular structure</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_6a26f42d-3b6c-41d4-bb51-37f2d81662c6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Neomycin sulfate is poorly absorbed from the gastrointestinal tract. The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function. The unabsorbed portion of the drug (approximately 97 percent) is eliminated unchanged in the feces.</p>
<p>Growth of most intestinal bacteria is rapidly suppressed following oral administration of neomycin sulfate, with the suppression persisting for 48 to 72 hours. Nonpathogenic yeasts and occasionally resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter</span> <span class="Italics">aerogenes </span>(formerly <span class="Italics">Aerobacter</span> <span class="Italics">aerogenes</span>) replace the intestinal bacteria.</p>
<p>As with other aminoglycosides, the amount of systemically absorbed neomycin transferred to the tissues increases cumulatively with each repeated dose administered until a steady state is achieved. The kidney functions as the primary excretory path as well as the tissue binding site with the highest concentration found in renal cortex. With repeated dosings, progressive accumulation also occurs in the inner ear. Release of tissue bound neomycin occurs slowly over a period of several weeks after dosing has been discontinued.</p>
<p>Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, this may be between 0 and 30 percent.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a7eea30d-3087-41e9-b60c-b0a62794ecb5"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Microbiology</span></h2>
<p class="First"><span class="Italics">In vitro</span> tests have demonstrated that neomycin is bactericidal and acts by inhibiting the synthesis of protein in susceptible bacterial cells. It is effective primarily against gram-negative bacilli but does have some activity against gram-positive organisms. Neomycin is active <span class="Italics">in vitro</span> against <span class="Italics">Escherichia coli</span> and the <span class="Italics">Klebsiella-Enterobacter</span> group. Neomycin is not active against anaerobic bowel flora.</p>
<p>If susceptibility testing is needed, using a 30 mcg disc, organisms producing zones of 16 mm or greater are considered susceptible. Resistant organisms produce zones of 13 mm or less. Zones greater than 13 mm and less than 16 mm indicate intermediate susceptibility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_9c6d8a93-e754-48d6-9cb6-12f01942aa00"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1bcca042-c69a-427d-b10b-1eacf47fdff1"></a><a name="section-4.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">Hepatic coma</span> (portal-systemic <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>)</span></h2>
<p class="First">Neomycin sulfate has been shown to be effective adjunctive therapy in <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> by reduction of the <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> forming bacteria in the intestinal tract. The subsequent reduction in blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> has resulted in neurologic improvement.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f567e5fd-cd62-458c-8578-6cf739d8f406"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Neomycin sulfate oral preparations are contraindicated in the presence of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> and in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
<p>Patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or serious toxic reaction to other aminoglycosides may have a cross-sensitivity to neomycin.</p>
<p>Neomycin sulfate oral solution is contraindicated in patients with inflammatory or ulcerative gastrointestinal disease because of the potential for enhanced gastrointestinal absorption of neomycin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_23f47e92-463b-4ecb-8d74-04c8aa87499f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">(<a href="#LINK_57c4c71c-d738-4816-8689-dc4de322c3c7">see boxed WARNINGS</a>)</p>
<p>Additional manifestations of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> may include <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, skin <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> continues after drug withdrawal.</p>
<p>Aminoglycosides can cause fetal harm when administered to a pregnant woman.</p>
<p>Aminoglycoside antibiotics cross the placenta and there have been several reports of total irreversible bilateral <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span> in children whose mothers received streptomycin during pregnancy. Although serious side effects to fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides, the potential for harm exists. Animal reproduction studies of neomycin have not been conducted. If neomycin is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_036fc6d1-5798-47c6-b24f-fa1e331a3760"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_48edafe4-c2cb-412c-83e4-63929c783857"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing Neomycin Sulfate Oral Solution in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>As with other antibiotics, use of oral neomycin may result in overgrowth of non-susceptible organisms, particularly fungi. If this occurs, appropriate therapy should be instituted.</p>
<p>Neomycin is quickly and almost totally absorbed from body surfaces (except the urinary bladder) after local irrigation and when applied topically in association with surgical procedures. Delayed-onset, irreversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> (regardless of the status of renal function) have been reported following irrigation of both small and large surgical fields with minute quantities of neomycin.</p>
<p>Cross-allergenicity among aminoglycosides has been demonstrated.</p>
<p>Aminoglycosides should be used with caution in patients with muscular disorders such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> since these drugs may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of their potential curare-like effect on the neuromuscular junction.</p>
<p>Small amounts of orally administered neomycin are absorbed through intact intestinal mucosa.</p>
<p>There have been many reports in the literature of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and/or <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> with the oral use of neomycin. If <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> develops during oral therapy, consideration should be given to reducing the drug dosage or discontinuing therapy.</p>
<p>An oral neomycin dose of 12 grams per day produces a <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span> for a variety of substances including fat, nitrogen, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin and iron.</p>
<p>Oral administered neomycin increases fecal bile acid excretion and reduces intestinal lactase activity.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_a04a76b2-2706-4863-8199-7a48b25e18dc"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> may develop toxic neomycin blood levels unless doses are properly regulated. If <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> develops during treatment, the dosage should be reduced or the antibiotic discontinued. To avoid <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and eighth <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> associated with high doses and prolonged treatment, the following should be performed prior to and periodically during therapy: urinalysis for increased excretion of protein, decreased specific gravity, casts and cells; renal function tests such as serum creatinine, BUN or creatinine clearance; tests of the vestibulocochlearis nerve (eighth cranial nerve) function.</p>
<p>Serial, vestibular and audiometric tests should be performed (especially in high risk patients). Since elderly patients may have reduced renal function which may not be evident in the results of routine screening tests such as BUN or serum creatinine, a creatinine clearance determination may be more useful.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_98ff29ef-83bf-400a-a334-e828218d5021"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution should be taken in concurrent or serial use of other neurotoxic and/or nephrotoxic drugs because of possible enhancement of the <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and/or <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> of neomycin (<a href="#LINK_57c4c71c-d738-4816-8689-dc4de322c3c7">see boxed WARNINGS</a> ).</p>
<p>Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin's <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and/or <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and potentiate neomycin's neuromuscular blocking effects.</p>
<p>Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorourcil. The gastrointestinal absorption of digoxin also appears to be inhibited. Therefore, digoxin serum levels should be monitored.</p>
<p>Oral neomycin may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_b9fa2144-2e65-48d5-b731-3df828c4e25a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term animal studies have been performed with neomycin to evaluate carcinogenic or mutagenic potential or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_6ba1a58d-6db8-4238-a4c4-c13ecef42ba3"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Category D (<a href="#LINK_23f47e92-463b-4ecb-8d74-04c8aa87499f">see WARNINGS section</a>)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_38dfc82d-1f89-48de-9aea-8e3afdc47032"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether neomycin is excreted in human milk but it has been shown to be excreted in cow milk following a single intramuscular injection. Other aminoglycosides have been shown to be excreted in human milk. Because of the potential for serious adverse reactions from the aminoglycosides in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ddb1af3f-4335-42da-88db-c04e98f31c47"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of oral neomycin in patients less than eighteen years of age have not been established. If treatment of a patient less than eighteen years of age is necessary, neomycin should be used with caution and the period of treatment should not exceed three weeks because of the absorption from the gastrointestinal tract.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_85d3664d-5c05-4c6b-bb88-882b46a59b30"></a><a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Neomycin Sulfate Oral Solution should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Neomycin Sulfate Oral Solution is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Neomycin Sulfate Oral Solution or other antibacterial drugs in the future.</p>
<p>Before administering the drug, patients or members of their families should be informed of possible toxic effects of the eighth nerve. The possibility of acute toxicity increases in premature infants and neonates.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_9cc8a4f4-0f87-470d-a9b4-17c00a90124f"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions to oral neomycin are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. The "<span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption Syndrome</span>" characterized by increased fecal fat, decreased serum carotene and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in xylose absorption has been reported with prolonged therapy. <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, and neuromuscular blockage have been reported (<a href="#LINK_57c4c71c-d738-4816-8689-dc4de322c3c7">see boxed WARNINGS</a> and <a href="#LINK_036fc6d1-5798-47c6-b24f-fa1e331a3760">PRECAUTIONS section</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_5e54fef0-a66a-4b4d-aa41-3928dfbf81d9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, and/or <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
<p>Hemodialysis will remove neomycin from the blood.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_1e02315b-b79a-4341-90c9-07cb5490628a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">To minimize the risk of toxicity use the lowest possible dose and the shortest possible treatment period to control the condition. Treatment for periods longer than two weeks is not recommended.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_36595a78-0556-4113-8167-662359fecc54"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">Hepatic coma</span></span></h2>
<p class="First">For use as an adjunct in the management of <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>, the recommended dose is 4 to 12 grams per day given in the following regimen:</p>
<ol class="Arabic">
<li><p class="First">Withdraw protein from diet. Avoid use of diuretic agents.</p></li>
<li><p class="First">Give supportive therapy including blood products, as indicated.</p></li>
<li>
<p class="First">Give NEO-FRADIN Oral Solution in doses of four to twelve grams of neomycin sulfate per day in divided doses.</p>
<p>Treatment should be continued over a period of five to six days during which time protein should be returned incrementally to the diet.</p>
</li>
<li><p class="First">If less potentially toxic drugs cannot be used for chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, neomycin sulfate in doses of up to four grams daily may be necessary. The risks for the development of neomycin induced toxicity progressively increase when the treatment must be extended to preserve the life of a patient with <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> who has failed to fully respond. Frequent periodic monitoring of these patients to ascertain the presence of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> is mandatory (<a href="#LINK_036fc6d1-5798-47c6-b24f-fa1e331a3760">see PRECAUTIONS</a>). Also, neomycin serum concentrations should be monitored to avoid potentially toxic levels. The benefits to the patient should be weighed against the risks of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, permanent <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> following the accumulation of neomycin in the tissues.</p></li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_278eee4d-158d-4712-9d9c-514c63401093"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NEO-FRADIN Oral Solution is available as a clear orange solution with a cherry flavor in 16 fl. oz bottle containing 125 mg of neomycin sulfate (equivalent to 87.5 mg of neomycin) per five mL.</p>
<p>NDC 39822-0330-5 for 16 fl. oz.</p>
<p><span class="Bold">Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</span></p>
<p>Manufactured for:</p>
<p>X-Gen Pharmaceuticals, Inc.</p>
<p>Big Flats, NY 14814</p>
<p>Revised April 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_6d80ce35-4874-4f09-ba26-116dd8f56c2b"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"> <img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5&amp;name=neo-fradin-solution-2.jpg"><p class="MultiMediaCaptionNotCentered">label</p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEO-FRADIN 		
					</strong><br><span class="contentTableReg">neomycin sulfate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:39822-0330</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">87.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZOIC ACID</strong></td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">0.75 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CHERRY</strong></td>
<td class="formItem">4.645 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">1.878 g  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">1.25 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</strong></td>
<td class="formItem">15 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIATOMACEOUS EARTH</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-0330-2</td>
<td class="formItem">59 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:39822-0330-5</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065010</td>
<td class="formItem">05/23/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>X-GEN Pharmaceuticals, Inc.
							(790169531)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3010aa62-7af6-438a-bbde-80d41975b8aa</div>
<div>Set id: aea1d3e4-604a-4680-91e2-cce6a128a1b5</div>
<div>Version: 9</div>
<div>Effective Time: 20120503</div>
</div>
</div> <div class="DistributorName">X-GEN Pharmaceuticals, Inc.</div></p>
</body></html>
